It has displayed significant anticancer activity against various types of cancer cells including RCC [31, 42], and it is hypothesized that dual PI3K/mTOR inhibitor NVP-BEZ235 is a promising antitumor agent against ccRCC. Here, MTOR is linked to nonpapillary renal cell carcinoma.